These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12432845)

  • 41. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
    N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erosion of psoriatic plaques: an early sign of methotrexate toxicity.
    Pearce HP; Wilson BB
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 2):835-8. PubMed ID: 8912599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methotrexate: understanding the risk in psoriasis patients.
    Lucas J; Ntuen E; Pearce DJ; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2009; 20(5):311-3. PubMed ID: 19363738
    [No Abstract]   [Full Text] [Related]  

  • 44. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
    Aydin F; Canturk T; Senturk N; Turanli AY
    Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Methotrexate in psoriasis: do we need to give a test dose?].
    Carretero-Hernández G
    Actas Dermosifiliogr; 2012; 103(1):1-4. PubMed ID: 22093543
    [No Abstract]   [Full Text] [Related]  

  • 46. Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate.
    Sako EY; Famenini S; Wu JJ
    J Am Acad Dermatol; 2013 Nov; 69(5):e264-e265. PubMed ID: 24124857
    [No Abstract]   [Full Text] [Related]  

  • 47. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
    Reich K; Langley RG; Papp KA; Ortonne JP; Unnebrink K; Kaul M; Valdes JM
    N Engl J Med; 2011 Oct; 365(17):1586-96. PubMed ID: 22029980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mood changes with methotrexate therapy for dermatologic disease.
    Bhat T; Coughlin CC
    Pediatr Dermatol; 2018 Mar; 35(2):253-254. PubMed ID: 29315793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis.
    Paul C; Le Tourneau A; Cayuela JM; Devidas A; Robert C; Molinié V; Dubertret L
    Arch Dermatol; 1997 Jul; 133(7):867-71. PubMed ID: 9236525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Noninvasive monitoring for methotrexate hepatotoxicity.
    MacDonald A; Burden AD
    Br J Dermatol; 2005 Mar; 152(3):405-8. PubMed ID: 15787807
    [No Abstract]   [Full Text] [Related]  

  • 52. The treatment of psoriasis vulgaris: 1% topical methotrexate gel.
    Eskicirak B; Zemheri E; Cerkezoglu A
    Int J Dermatol; 2006 Aug; 45(8):965-9. PubMed ID: 16911386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methotrexate induced pericarditis and pericardial effusion in psoriatic patient.
    Palungwachira P; Palungwachira P; Laohathai P
    J Med Assoc Thai; 1998 Feb; 81(2):141-5. PubMed ID: 9529845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methotrexate and psoriasis: consensus conference.
    Kalb RE; Strober B; Weinstein G; Lebwohl M
    J Am Acad Dermatol; 2011 Jun; 64(6):1179. PubMed ID: 21571176
    [No Abstract]   [Full Text] [Related]  

  • 55. Methotrexate, hyperosmia, and migraine.
    Zargari O
    Dermatol Online J; 2006 Dec; 12(7):28. PubMed ID: 17459314
    [No Abstract]   [Full Text] [Related]  

  • 56. Methotrexate use and liver disease--a causal relationship?
    Schmitt J; Singh JA
    Br J Dermatol; 2014 Jul; 171(1):6-7. PubMed ID: 25066285
    [No Abstract]   [Full Text] [Related]  

  • 57. Pulmonary toxicity in a patient with psoriasis receiving methotrexate therapy.
    McKenna KE; Burrows D
    Clin Exp Dermatol; 2000 Jan; 25(1):24-7. PubMed ID: 10671965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe vertigo requiring hospitalization whilst taking low-dose oral methotrexate for psoriasis.
    Swale VJ; Sahota A
    Clin Exp Dermatol; 2005 May; 30(3):295-6. PubMed ID: 15807694
    [No Abstract]   [Full Text] [Related]  

  • 59. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
    Ho SG; Yeung CK; Chan HH
    Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.
    Shalom G; Zisman D; Harman-Boehm I; Biterman H; Greenberg-Dotan S; Polishchuk I; Moser H; Freud T; Feldhamer I; Cohen AD
    Acta Derm Venereol; 2015 Nov; 95(8):973-7. PubMed ID: 25950855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.